Home › New KEYTRUDA (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
 

Keywords :   


New KEYTRUDA (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

2016-11-07 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancers (SITC) 31st Annual Meeting, Nov. 9-13. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data meeting accepted annual

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.05Personal Care Products Council Elects Greenberg as New Board Chair
02.05RIFM Senior Scientist To Present at HCPA Mid-Year Meeting
02.05Apex stresses sustainability with EcoProven GTT at drupa
02.05Durst announces 1,000th installation of Durst Workflow software
02.05Milestone for Transition to Sustainable Carbon in Europe
02.05Blue Lizard Is Official Sunscreen for Dollywood Resort Parent Company Herschend
02.05Illinois Bacon Day shines light on state's pork industry
02.05Hospeco Completes Integration of Innocore
More »